CEN Biotech, Inc.
CENBF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | -0.02 | -0.57 |
| FCF Yield | -17.48% | -5.22% | -0.53% | -1.61% |
| EV / EBITDA | -10.10 | -0.81 | 4.13 | -39.15 |
| Quality | ||||
| ROIC | -43.09% | -489.67% | -80.77% | 59.73% |
| Gross Margin | 50.45% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.22 | 0.02 | -0.02 | 0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | -36.47% | 60.80% | 49.73% |
| Safety | ||||
| Net Debt / EBITDA | -6.65 | -0.30 | 0.62 | -10.76 |
| Interest Coverage | -5.00 | -22.48 | -0.60 | -0.78 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -24,330.26 | 0.00 |
| Cash Conversion Cycle | -242.35 | 133.04 | -159.84 | -25.64 |